Proposal to list respiratory care products supplied by MedXus Limited
PHARMAC is seeking feedback on a proposal to list a range of respiratory equipment and consumable devices in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019, through a provisional agreement with MedXus Limited.
Consultation closes at 4pm on Thursday, 28 February 2019.
Proposal to list surgical suction, chest and wound drainage products
PHARMAC is seeking feedback on a proposal to list a range of surgical suction, chest and wound drainage products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019 through provisional amendments to the Agreements with Conva Tec (New Zealand) Limited, Defries Industries NZ Limited and Laerdal (New Zealand) Limited.
Closes: 4pm Monday, 25 February 2019.
Proposal to list endomechanical and electrosurgical medical devices supplied by Hallmark Surgical Limited
PHARMAC is seeking feedback on a proposal to list a range of endomechanical and electrosurgical medical devices on Section H Part III of the Pharmaceutical Schedule from 1 April 2019 through a listing agreement with Hallmark Surgical Limited.
Closes: 5pm, Monday 25 February 2019.
Decision to open access to atomoxetine and change funded brand
We’re pleased to announce that all funding restrictions on atomoxetine will be removed from 1 July 2019. We will also be changing the funded brand of atomoxetine; Generic Partners’ brand will be listed from 1 July 2019; and, after a transition period the current brand Strattera will be delisted on 1 December 2019.
Proposal to list continence products supplied by Asaleo Care New Zealand Limited
PHARMAC is seeking feedback on a proposal to list a range of continence products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019, though a listing agreement with Asaleo Care New Zealand Limited.
Closes: 4pm Friday, 22 February 2019.
January 2019 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2017/18 Invitation to Tender, dated 2 November 2017.
Proposal to list medical devices supplied by Universal Specialities Limited (USL Medical)
PHARMAC is seeking feedback on a proposal to list a range of needles and syringes in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019, through a non-exclusive provisional agreement with Universal Specialities Limited.
Closes: 4pm Wednesday, 20 February 2019.
Proposal to change the funded brand of oral flecainide acetate
We propose the following changes to the funded brands of oral flecainide used in the prevention of supraventricular and ventricular arrhythmias.
Closes: 4 pm on Monday, 18 February 2019.
Proposal for changes to funded haemophilia treatments
We are proposing to make changes to the funding of haemophilia treatments from 1 May 2019, including funding of new extended half-life treatments. These changes would mean that most people with haemophilia would need to change brands, but there would be an increase in the range of funded treatment options available with extended-half-life treatments becoming funded for the first time.
Closes: 4 pm on Monday, 18 February 2019
Proposal to list medical devices
PHARMAC is seeking feedback on a proposal to list medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019.
Closes: 4pm Monday, 18 February 2019.
Proposal to list medical devices supplied by Culpan Distributors Ltd
PHARMAC is seeking feedback on a proposal to list a range of needles and syringes in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019, through a provisional agreement with Culpan Distributors Ltd.
Closes: 4pm Thursday, 13 February 2019.
Decision to list needles and syringes products supplied by B. Braun New Zealand Pty Limited
We are pleased to announce a listing agreement with B. Braun New Zealand Pty Limited (“B. Braun”) for the supply of needles and syringes products to DHBs.
Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit and hyperactivity disorder
- We’re pleased to announce the approval of a multiproduct agreement with Teva Pharma New Zealand Limited (Teva) which will result in the following:
- funding a new pack size of modafinil (Modavigil), 60 tab pack, for narcolepsy in conjunction with a price decrease for the 30 tab pack, from 1 February 2019;
- funding a new brand of methylphenidate hydrochloride extended-release tablets (Methylphenidate ER - Teva) for attention deficit and hyperactivity disorder (ADHD) subject to the same restrictions as the Concerta and Ritalin LA brands of methylphenidate hydrochloride extended-release, following Medsafe approval;
- funding a new 40 mg formulation of glatiramer acetate (Copaxone) prefilled syringes, which would mean fewer injections for people taking this medicine, from 1 February 2019;
- delisting the current 20 mg formulation of glatiramer acetate (Copaxone) prefilled syringes from 1 July 2019.
Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
We’re pleased to announce PHARMAC’s decision to approve a multiproduct agreement with Merck Sharpe & Dohme (MSD). This will result in the listing of a new, once-daily presentation of raltegravir for the treatment of HIV, once it is registered with Medsafe, as well as changes to the contractual arrangements for the currently funded presentations of raltegravir and posaconazole.
Agreement for the supply of orthopaedic products supplied by NuVasive (AUST/NZ) Pty Limited
We are pleased to announce the approval of a listing agreement with NuVasive (AUST/NZ) Pty Limited (“NuVasive”) for the supply of their range of orthopaedic implants and associated products (“Orthopaedic Products”) to DHBs.
December 2018 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2017/18 Invitation to Tender, dated 2 November 2017.
Decisions relating to the funded brands of some antiretroviral treatments for HIV
We’re pleased to announce decisions to award sole supply for seven antiretroviral treatments (ARTs) used in the treatment of HIV infection.
Decision to list ostomy products supplied by Omnigon Pty Ltd
We are pleased to announce the approval of a non-exclusive listing agreement with Omnigon Pty Ltd (“Omnigon”) for the supply of ostomy products to DHBs.
Decision to list medical devices supplied by Medtronic
We’re pleased to announce of a listing agreement with Medtronic New Zealand Limited (“Medtronic”) for the supply of needles and syringes products.
Proposal to amend the distribution and access criteria for dasatinib (Sprycel)
PHARMAC is seeking feedback on a proposal to amend the distribution arrangements and access criteria for the funding of dasatinib (Sprycel) tablets for chronic myeloid leukaemia (CML) from 1 May 2019.
Closes: 5 pm on Wednesday, 30 January 2019
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Hospital News: News about getting the best value for what we spend on hospital pharmaceuticals.
Inpharmation: News about PHARMAC's activities and pharmaceutical-related issues.
Inpharmation in Hospitals: Hospital news about PHARMAC's activities and pharmaceutical-related issues.
Te Whaioranga ePānui: A PHARMAC newsletter for people with an interest in Māori health.
